Peripheral Neuropathy and Neuropathic Pain

Characteristics of Neuropathic Pain

• Patients with peripheral neuropathy often experience burning pain, "electrical shock" sensations, stabbing or knife-like pains, and uncomfortable tingling (paresthesia), with up to 50% of patients being affected by neuropathic pain 1, 2
• Many patients experience allodynia (pain from normally non-painful stimuli like clothing touching the skin) 1
• Discomfort while walking may be described as "walking barefoot on marbles" or "walking barefoot on hot sand" 2
• Altered temperature perceptions are common, with feet feeling abnormally warm or cold 2
• Pain is characteristically more severe at night, often resulting in sleep disturbance 1
• Symptoms typically begin distally (feet) and may progress proximally up the limbs 2

Pathophysiological Mechanisms

• Peripheral mechanisms of neuropathic pain include changes in sodium and calcium channel distribution and expression, altered neuropeptide expression, peripheral sensitization, damage to small nerve fibers, and axonal atrophy, degeneration or regeneration 3
• Central mechanisms of neuropathic pain include central sensitization, Aβ fiber sprouting into lamina II of the dorsal horn, and reduced inhibition via descending pathways 3

Clinical Impact of Neuropathic Pain

• The presence of neuropathic pain significantly impacts quality of life, causing severe sleep disturbance, leading to fatigue and reduced daily activities 1
• Neuropathic pain is associated with profound depression and anxiety, with over two-thirds of patients with painful diabetic neuropathy having anxiety and/or depression 1
• Neuropathic pain leads to limitations in daily activities and poor satisfaction with treatments 2

Diagnostic Considerations

• Neuropathic pain is defined as "pain arising as a direct consequence of abnormalities in the somatosensory system" 2
• Peripheral neuropathic pain is invariably symmetrical; asymmetrical symptoms should prompt investigation for other etiologies 3
• Various validated scales can assess pain characteristics, including visual analog scales, numerical rating scales, and specific neuropathic pain questionnaires 3

Treatment Implications

• First-line therapies for neuropathic pain include tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors (SNRIs), and anticonvulsants like pregabalin and gabapentin 4, 5
• Duloxetine is specifically recommended for neuropathic pain, numbness, and tingling 6
• Physical activity is also recommended as a non-pharmacological approach 6

Peripheral Neuropathy with Neuropathic Pain

Diagnosis

• Burning pain and "electrical shock" sensations are hallmark descriptors of neuropathic pain affecting small nerve fibers, according to the American Diabetes Association 7
• Altered temperature perception (feeling heat after cold exposure) indicates dysfunction of small C-fibers (heat sensation) and Aδ-fibers (cold sensation), as noted by the American Diabetes Association 7
• Needle-like sensations (paresthesias) represent abnormal firing of damaged sensory nerves, as described by the American Diabetes Association 7
• Physical examination should specifically assess small fiber function, large fiber function, and protective sensation, as recommended by the American Diabetes Association 8
• Standard nerve conduction studies may be completely normal in small fiber neuropathy, as these tests only evaluate large myelinated fibers, according to the American Society of Clinical Oncology 9

Treatment Approach

• The American Diabetes Association recommends initiating treatment with pregabalin, duloxetine, or gabapentin as first-line agents for neuropathic pain 8
• Pregabalin, duloxetine, and gabapentin have proven efficacy in reducing neuropathic pain, with 38% of patients achieving ≥50% pain reduction at optimal dosing, as reported by the American Diabetes Association 8
• Addressing underlying etiology aggressively, such as optimizing glycemic control in diabetic patients, is crucial in managing neuropathic pain, as emphasized by the American Diabetes Association 8
• Physical activity and exercise are recommended as adjunctive non-pharmacological approaches, with early evidence suggesting protective effects on neuropathy progression, according to the American Society of Clinical Oncology 9
• The Mayo Clinic advises against using prolonged cold water immersion or ice application for symptom relief, as it can lead to immersion foot, skin ulceration, and infection risk 10
• Monitoring for depression and anxiety is essential, as over two-thirds of patients with painful neuropathy develop anxiety and/or depression, and addressing psychological comorbidities improves overall pain outcomes, as noted by the American Diabetes Association 7

Diagnostic Approach to Small Fiber Neuropathy

Essential Diagnostic Workup

• The American Diabetes Association recommends screening for diabetes mellitus (fasting glucose, HbA1c) as diabetic neuropathy is the most common cause of small fiber neuropathy 11
• The European Association for the Study of Diabetes suggests excluding secondary causes of neuropathy before confirming the diagnosis, including screening for diabetes mellitus (fasting glucose, HbA1c) 12

Diagnosis and Management of Painful Diabetic Peripheral Neuropathy

Diagnostic Considerations

• The American Diabetes Association recommends checking for peripheral arterial disease by assessing pedal pulses and ankle-brachial index in patients with diabetic peripheral neuropathy 13
• The presence of bilateral symmetric distribution of pain, starting distally and progressing proximally, is a key diagnostic feature of diabetic peripheral neuropathy, as noted by the Diabetes/Metabolism Research and Reviews 14
• Lumbar radiculopathy should be considered in the differential diagnosis, but it typically presents with asymmetric and dermatomal pain, according to the Diabetes/Metabolism Research and Reviews 14

Pain Management

• The American College of Cardiology recommends initiating treatment with duloxetine 30 mg daily, titrating to 60 mg daily after one week, for the management of painful diabetic peripheral neuropathy 14
• Pregabalin and gabapentin are alternative first-line options, with pregabalin starting at 75 mg twice daily and gabapentin starting at 300 mg daily, as suggested by the Diabetes/Metabolism Research and Reviews 14
• The American Heart Association recommends targeting HgA1c <7% to slow neuropathy progression, as stated in the Circulation journal 15

Non-Pharmacological Strategies

• The American College of Sports Medicine recommends supervised exercise therapy to improve pain-free walking distance and maximum walking distance in patients with painful diabetic peripheral neuropathy, as noted in the Circulation journal 15
• Well-fitted walking shoes or athletic shoes with cushioning can help redistribute plantar pressure and alleviate pain, according to the Diabetes Care journal 13
• Podiatry referral is recommended for custom orthotics if needed, as suggested by the Diabetes Care journal 13 and the Diabetes/Metabolism Research and Reviews 16

Optimal Drug Classes

• The American Academy of Neurology recommends using neuromodulators, such as SNRIs (duloxetine) and anticonvulsants (pregabalin, gabapentin), as first-line treatment for neuropathic pain, as stated in the Diabetes/Metabolism Research and Reviews 14
• Tricyclic antidepressants (amitriptyline) should be used with caution due to their potential for orthostatic hypotension, cardiac arrhythmias, and anticholinergic effects, as noted by the Diabetes/Metabolism Research and Reviews 14